BIIB - Will Biogen Q4 earnings bring positive surprise amid Aduhelm woes?

Biogen (NASDAQ:BIIB) is scheduled to announce Q4 earnings results on Thursday, February 3rd, before market open. The consensus EPS Estimate is $3.38 (-26.2% Y/Y) and the consensus Revenue Estimate is $2.62B (-8.1% Y/Y). Over the last 2 years, BIIB has beaten EPS estimates 88% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 8 upward revisions and 10 downward. Revenue estimates have seen 5 upward revisions and 11 downward. The company's stock was down -0.58% on Oct. 20, the day it reported its Q3 results. The company had upgraded its 2021 guidance following better than expected revenue for Q3. However, the sales of key drugs in its portfolio continued to decline. For Q3 Alzheimer’s medication Aduhelm recorded only $0.3M in revenue, compared to $2M in Q2. Aduhelm News:  Aduhelm' woes have continued as in January 2022, the Centers for Medicare and Medicaid

For further details see:

Will Biogen Q4 earnings bring positive surprise amid Aduhelm woes?